Neurolief, a neuroscience-driven medical technology company developing brain neuromodulation therapies for mental health and neurological conditions, is bringing two prescription therapies to U.S. veterans through a new Department of Veterans...
Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent...
Today, resbiotic® the physician-developed microbiome health company headquartered in Dallas, Texas, announced the launch of two of its science-backed microbiome formulas — resB® Lung Support Probiotic and resG prebeet® Prebiotic — at H-E-B stores...
InstaMed® Pharmaceuticals, an advanced biotechnology company transforming peptide delivery through its patented InstaRelease® oral dissolving strip platform, announced the appointment of Tracy Gibbs, PhD, as Chief Executive Officer. The leadership...
Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the National Medical Products Administration of China...
Starting today FDA-approved Wegovy® (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity. Obesity is a serious, common chronic disease among older Americans and Wegovy®...
Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX) today announced the launch of KYMBEE™ (deflazacort) Oral Suspension, 22.75 mg/mL indicated for the treatment of Duchenne...
Incyte announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to...
VERTANICAL announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic low back pain with a radicular (neuropathic) component. The authorization marks a major milestone for VERTANICAL and highlights...
Alpha Cognition Inc. a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, announced the top-line results from its BEACON real-world study evaluating provider-reported cognitive, behavioral,...
Beauty Crush Skincare, the latest venture from innovative beauty leader Karen Behnke, debuts and once again introduces formulas that challenge the industry with a new era of regenerative biotechnology-driven skincare. The collection combines a...
Nestlé Health Science, a global leader in the science of nutrition, and IdB Holding S.p.A. (IdB), a global leader in the production of high potent active pharmaceutical ingredients for the pharmaceutical and the health food industries, announced...
H. Lundbeck A/S (Lundbeck) announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorization for eptinezumab for use in adults with migraine. Migraine is a progressive and debilitating neurological...
Ferring Pharmaceuticals announced a new real-world case series demonstrating that re-induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in approximately 31% (4/13) of patients with high-risk Bacillus...
As chronic conditions tied to metabolic health continue to rise across the United States, MinuteClinic®, the medical clinic inside select CVS Pharmacy® locations, is highlighting its clinically supervised weight-loss program to support earlier...
Women's health supplement brand Ritual in partnership with Brooklyn College (CUNY) announced the publication of the folate results from their clinical trial on their top-selling Essential Prenatal in the journal Frontiers in Nutrition. The...
Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. Ozempic® is the only FDA-approved oral peptide GLP-1 medication for adults with...
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who...
YARAL Pharma Inc. the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), announced that its Diclofenac Epolamine Topical System 1.3%, the authorized generic of Flector® (diclofenac epolamine) topical system 1.3%, is now...
SQ Innovation, developer of Lasix® ONYU, announced two important regulatory milestones in its international expansion strategy: the receipt of a CE marking certificate for the Lasix ONYU device, and the acceptance of Lasix ONYU by the European...
